Proper biomarker validation is frequently missing, so many findings in the literature are false positive results. In this study in >3700 pts germline HLA landscape does not predict efficacy of pembrolizumab monotherapy across several solid tumor types. Tweet added by Giampaolo Bianchini @BianchiniGP

Giampaolo Bianchini

2 years

Proper biomarker validation is frequently missing, so many findings in the literature are false positive results. In this study in >3700 pts germline HLA landscape does not predict efficacy of pembrolizumab monotherapy across several solid tumor types.

Germline HLA landscape does not predict efficacy of pembrolizumab monotherapy across solid tumor...

Germline HLA diversity has been suggested as a biomarker of response to immune checkpoint inhibitors. Chhibber, Huang, Zhang et al. analyze 3,500 patients across 17 pembrolizumab clinical trials and...